There's an unmistakable odour causing quite a stir among the writers of The Spectator. 

How will European CBD businesses be affected? Recent to the European Union’s Novel Foods Catalogue have occurred regarding the use of cannabidiol (CBD), other cannabinoids and hemp-derived products in food.

In 2018 our work took us to eleven countries as we bolstered our team with talented people in five cities central to the future of cannabis, and conceived projects that reflect the multifaceted potential of this industry. Here are just a few of the moments and highlights that made 2018 our best year yet…

As a variety cannabis products are introduced into the medical field, both industry and institutions are facing the challenges of a new, rapidly-evolving policy environment being built on the backbone of an old and strained system of medical regulations.

Hanway Associates is proud to announce that we have become the first European member of the Global Cannabis Partnership (GCP).

The French National Agency for Medicines and Health Products Safety, ANSM, recommended last Thursday the implementation of a medical cannabis regime in France.

Hanway Associates hire new CFO, Sam Lewis, from PwC.

Today the newly formed government of Luxembourg announced that the country plans to legalise recreational cannabis.

The past six months have seen an unprecedented rate of change for both the global and European cannabis industry. Today, for the first time, patients across the United Kingdom will be able to be prescribed a range of cannabis-based medicinal products.

In a historic event that will be closely watched across the world, Canada today becomes the first G7 country to legalise cannabis for recreational use.

Cannabis Europa Paris will take place on 8 February 2019, and Cannabis Europa London will take place on the 24-25 June 2019.

The UK government has laid historic new regulations rescheduling cannabis-based medicine, which will come into force on 1st November 2018.

The French Agency for Medicines and Healthcare Products Safety (ANSM) has published the list of the members who will make up the Special Committee charged with the review of medical cannabis benefits in France.

Hanway Associates CEO George McBride spoke at the Conservative Party Conference and Cannabis Invest UK this week on developments in the UK and European Cannabis industry.

On September 21st the UK government announced how they would define cannabis-based products for medicinal use. Following the conclusion of the two part review by the Chief Medical Officer and the ACMD on July 25th, Home Secretary Sajid Javid committed to swift action on the matter, and promised that these products would be lawful by autumn.

On Monday 10th September, the National Agency for Health and Medicines (ANSM) announced the creation of a special committee to review the evidence supporting the effectiveness of medical cannabis.

Yesterday, the UK’s Advisory Council on the Misuse of Drugs’ new (non-binding) advice to the Home Office on medical cannabis was published.

This is the first in a blog series profiling exciting companies, projects and people who are paving the way in the UK cannabis space. Separating The Strains is a documentary, currently in production, that explores medical cannabis treatments for epilepsy patients and others. 

Hanway Associates is pleased to announce another addition to our team. Pierre-Yves Galléty is joining us as a Project Manager.

Over the next 6 ½ weeks in the build up to the conference we will be making a series of exciting announcements including a raft of new speakers, sponsors and events.